# Lilly expands access to Zepbound® for adults with obesity – Lilly releases Zepbound® (tirzepatide) in single-dose vials – This expansion aims to provide more supply and access for adults living with obesity – The single-dose vials offer convenience and flexibility for patients and healthcare providers – Zepbound® is part of Lilly’s commitment to addressing the challenges of obesity Lilly’s release of Zepbound® single-dose vials represents a significant step in expanding access to effective treatments for adults dealing with obesity. By providing more supply and access, Lilly is demonstrating its dedication to improving the lives of those affected by obesity. The convenience and flexibility offered by the new vials will benefit both patients and healthcare providers, making it easier to adhere to treatment regimens. This expansion underscores Lilly’s ongoing commitment to tackling the complexities of obesity and promoting overall well-being. — Contact Mindful Evolution on our website https://yourmindfulevolution.com or call or text us at 954-639-9960 for more information on weight loss solutions. Weight loss disclaimer: Individual results may vary. Mindful Evolution offers telehealth services in Alabama, Arkansas, Florida, Georgia, Louisiana, Mississippi, North Carolina, New York, South Carolina, Tennessee, Texas, and Virginia.